

FIG. 1A



FIG. 1B



FIG. 1C



FIG. 1D



FIG. 1E


Tumor Growth Inhibition (TGI) %
100
50
0
No combo benefit
Combo benefit
Synergistic
PD-(L)1 TGI
Niraparib TGI
Combo TGI
4T1
EMT6
LLC1
E0771
BR6004
BR1126
KLN205
MDA-MB-436
BRKras
SK6005
SA9003
BL6078
MC38
LPA-T22
BRCA
tumor type
PD-1/PD-L1
Niraparib
WT breast PD1 full
WT breast PD1 full
WT lung PD1 full
WT breast PD1 full
WT breast PD1 full
WT TBD breast PD1 sub
WT lung PD1 full
WT breast PD1 sub
MUT ovary PD1 sub
WT skin PD1 sub
WT sarcoma PD1 full
WT bladder PDL1 full
WT colon PD1 full
WT breast PD1 full

FIG. 2



FIG. 3A



FIG. 3B



FIG. 3C

FIG. 3D


MDA-MB-436
BRCA1 mutant breast
Control
Niraparib
Anti-PD-1
Anti-PD-1 + niraparib
Tumor volume (mm3)
1500
1000
500
0
0
5
10
15
20
25
30
Time (days)

FIG. 3E


SK6005
APCMin/+ mutant skin
Control
Niraparib
Anti-PD-1
Anti-PD-1 + niraparib
Tumor volume (mm3)
3000
2000
1000
0
0
5
10
15
20
Time (days)



FIG. 4A



FIG. 4B



FIG. 4C



FIG. 4D


Vehicle
anti mPD-1 10mgk (Q3DX2 3off)X3
Niraparib 50mgk QD
Niraparib 30mgk QD
Niraparib 50mgk +anti mPD-1
Niraparib 30mgk +anti mPD-1
Tumor Volume (mm³)
2000
1500
1000
500
0
Vehicle
70 75 80 85 90 95 100 105 110 115 120
Study Day
Anti-mPD-1 (10 mg/kg)
Niraparib (30 mg/kg)
Niraparib (50 mg/kg)
Niraparib (30 mg/kg) + anti-mPD-1 (10 mg/kg)
Niraparib (50 mg/kg) + anti-mPD-1 (10 mg/kg)

FIG. 4E


% of M-MDSC (of CD11b+)
8
6
4
2
0
Vehicle
anti-PD-1
Niraparib (30 mg/kg)
Niraparib (50 mg/kg)
Niraparib (30 mg/kg) + anti-PD-1
Niraparib (50 mg/kg) + anti-PD-1
Vehicle
Anti-PD-1
Niraparib (30 mg/kg)
Niraparib (50 mg/kg)
Niraparib (30 mg/kg) + anti-PD-1
Niraparib (50 mg/kg) + anti-PD-1

FIG. 4F